Items where Author is "Hartung, H. P."

Article

Havla, J. and Warnke, C. and Derfuss, T. and Kappos, L. and Hartung, H. P. and Hohlfeld, R.. (2016) Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt international , 113 (51-52). pp. 879-886.

Derfuss, T. and Curtin, F. and Guebelin, C. and Bridel, C. and Rasenack, M. and Matthey, A. and Du Pasquier, R. and Schluep, M. and Desmeules, J. and Lang, A. B. and Perron, H. and Faucard, R. and Porchet, H. and Hartung, H. P. and Kappos, L. and Lalive, P. H.. (2015) A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 21 (7). pp. 885-893.

Derfuss, T. and Curtin, F. and Guebelin, C. and Bridel, C. and Rasenack, M. and Matthey, A. and Du Pasquier, R. and Schluep, M. and Desmeules, J. and Lang, A. B. and Perron, H. and Faucard, R. and Porchet, H. and Hartung, H. P. and Kappos, L. and Lalive, P. H.. (2015) A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. Journal of Neuroimmunology, 285. pp. 68-70.

Kuhle, J. and Disanto, G. and Dobson, R. and Adiutori, R. and Bianchi, L. and Topping, J. and Bestwick, J. P. and Meier, U. C. and Marta, M. and Dalla Costa, G. and Runia, T. and Evdoshenko, E. and Lazareva, N. and Thouvenot, E. and Iaffaldano, P. and Direnzo, V. and Khademi, M. and Piehl, F. and Comabella, M. and Sombekke, M. and Killestein, J. and Hegen, H. and Rauch, S. and D'Alfonso, S. and Alvarez-Cermeno, J. C. and Kleinova, P. and Horakova, D. and Roesler, R. and Lauda, F. and Llufriu, S. and Avsar, T. and Uygunoglu, U. and Altintas, A. and Saip, S. and Menge, T. and Rajda, C. and Bergamaschi, R. and Moll, N. and Khalil, M. and Marignier, R. and Dujmovic, I. and Larsson, H. and Malmestrom, C. and Scarpini, E. and Fenoglio, C. and Wergeland, S. and Laroni, A. and Annibali, V. and Romano, S. and Martinez, A. D. and Carra, A. and Salvetti, M. and Uccelli, A. and Torkildsen, O. and Myhr, K. M. and Galimberti, D. and Rejdak, K. and Lycke, J. and Frederiksen, J. L. and Drulovic, J. and Confavreux, C. and Brassat, D. and Enzinger, C. and Fuchs, S. and Bosca, I. and Pelletier, J. and Picard, C. and Colombo, E. and Franciotta, D. and Derfuss, T. and Lindberg, R. and Yaldizli, O. and Vecsei, L. and Kieseier, B. C. and Hartung, H. P. and Villoslada, P. and Siva, A. and Saiz, A. and Tumani, H. and Havrdova, E. and Villar, L. M. and Leone, M. and Barizzone, N. and Deisenhammer, F. and Teunissen, C. and Montalban, X. and Tintore, M. and Olsson, T. and Trojano, M. and Lehmann, S. and Castelnovo, G. and Lapin, S. and Hintzen, R. and Kappos, L. and Furlan, R. and Martinelli, V. and Comi, G. and Ramagopalan, S. V. and Giovannoni, G.. (2015) Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 21 (8). pp. 1013-1024.

Kappos, L. and Bates, D. and Edan, G. and Eraksoy, M. and Garcia-Merino, A. and Grigoriadis, N. and Hartung, H. P. and Havrdova, E. and Hillert, J. and Hohlfeld, R. and Kremenchutzky, M. and Lyon-Caen, O. and Miller, A. and Pozzilli, C. and Ravnborg, M. and Saida, T. and Sindic, C. and Vass, K. and Clifford, D. B. and Hauser, S. and Major, E. O. and O'Connor, P. W. and Weiner, H. L. and Clanet, M. and Gold, R. and Hirsch, H. H. and Radu, E. W. and Sorensen, P. S. and King, J.. (2011) Natalizumab treatment for multiple sclerosis : updated recommendations for patient selection and monitoring. The Lancet neurology, Vol. 10, H. 8. pp. 745-758.

Farrell, R. and Bendtzen, K. and Bertolotto, A. and Clark, B. and Comabella, M. and Deisenhammer, F. and Fogdell-Hahn, A. and Giovannoni, G. and Hartung, H. P. and Hemmer, B. and Hillert, J. and Kappos, L. and Killestein, J. and Lindberg, R. and Montalban, X. and Polman, C. and Sorensen, P. S. and European, Nabinms Consortium. (2008) Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of international medical research, Vol. 36, H. 1 , S. 204-208 ; author reply 208-210.

Polman, C. and Kappos, L. and Freedman, M. S. and Edan, G. and Hartung, H. P. and Miller, D. H. and Montalbán, X. and Barkhof, F. and Selmaj, K. and Uitdehaag, B. M. and Dahms, S. and Bauer, L. and Pohl, C. and Sandbrink, R. and Benefit, investigators. (2008) Subgroups of the BENEFIT study : risk of developing MS and treatment effect of interferon beta-1b. Journal of neurology, Vol. 255, H. 4. pp. 480-487.